Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | XBP1 | P17861 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | KDM4A | O75164 | 1/20 | 0.43 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.42 |
| ▸ | F2 | P00734 | 1/20 | 0.42 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL711731 | 0.88 | IDO1 (0.50) | IDO1GAAALDH1A1HPGDHTT | |
| SCHEMBL6920257 | 0.86 | IDO1 (0.55) | IDO1GAAALDH1A1HPGDHTT | |
| SCHEMBL27988801 | 0.86 | IDO1 (0.53) | IDO1GAAALDH1A1HPGDHTT | |
| SCHEMBL6921464 | 0.86 | IDO1 (0.50) | IDO1GAAALDH1A1HPGDHTT | |
| SCHEMBL23997640 | 0.84 | IDO1 (0.52) | IDO1GAAALDH1A1HPGDHTT | |
| SCHEMBL3734185 | 0.84 | ANO1 (0.51) | IDO1GAAALDH1A1HPGDHTT | |
| SCHEMBL30079765 | 0.84 | IDO1 (0.52) | IDO1GAAALDH1A1HPGDHTT | |
| SCHEMBL20446470 | 0.84 | IDO1 (0.52) | IDO1GAAALDH1A1HPGDHTT | |
| SCHEMBL1197122 | 0.84 | IDO1 (0.47) | IDO1GAAALDH1A1HPGDHTT | |
| SCHEMBL4757294 | 0.83 | GAA (0.49) | IDO1GAAALDH1A1HPGDHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2922535-B1 | THROMBIN INHIBITORS | MERCK SHARP & DOHME (US) | 2021-11-10 | — | — | EP | disclosed |
| US-9469608-B2 | Thrombin inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-10-18 | — | — | US | disclosed |
| US-20150315141-A1 | Thrombin Inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-11-05 | — | — | US | disclosed |
| WO-2014025658-A1 | PYRROLIDINE THROMBIN INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-02-13 | — | — | WO | disclosed |
| US-6610701-B2 | For therapy and prophylaxis of blood coagulation and cardiovascular disorders | MERCK & CO., INC. | 2003-08-26 | — | — | US | disclosed |
| US-20030158218-A1 | Thrombin inhibitors | NANTERMET PHILIPPE G (US) | 2003-08-21 | — | — | US | disclosed |
| US-6528503-B2 | Anticoagulants | MERCK & CO., INC. | 2003-03-04 | — | — | US | disclosed |
| US-6515011-B2 | Anticoagulants | MERCK & CO., INC. | 2003-02-04 | — | — | US | disclosed |
| US-20030013700-A1 | Thrombin inhibitors | MERCK SHARP & DOHME CORP. | 2003-01-16 | — | — | US | disclosed |
| US-20020193398-A1 | Thrombin inhibitors | MERCK & CO., INC. | 2002-12-19 | — | — | US | disclosed |
| US-20020119992-A1 | Thrombin inhibitors | MERCK & CO., INC. | 2002-08-29 | — | — | US | disclosed |
| WO-2002064211-A1 | THROMBIN INHIBITORS | MERCK & CO., INC. (US) | 2002-08-22 | — | — | WO | disclosed |
| WO-2002057225-A2 | THROMBIN INHIBITORS | MERCK & CO., INC. (US) | 2002-07-25 | — | — | WO | disclosed |
| WO-2002050056-A1 | BENZYLAMINE DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS | MERCK & CO., INC. (US) | 2002-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150315141-A1 | Thrombin Inhibitors | F3, F2, F9 | IDO1 3149/4885GAA 4869/4885ALDH1A1 4066/4885 |
| US-20030013700-A1 | Thrombin inhibitors | TFPI, PLAT, TFPI2 | IDO1 1438/4885GAA 3087/4885ALDH1A1 2961/4885 |
| US-20020119992-A1 | Thrombin inhibitors | SERPINC1, F2, TFPI | IDO1 2641/4885GAA 4559/4885ALDH1A1 4773/4885 |
| US-20030158218-A1 | Thrombin inhibitors | F2, SERPINC1, TFPI | IDO1 1670/4885GAA 4051/4885ALDH1A1 4206/4885 |
| US-20020193398-A1 | Thrombin inhibitors | F2, F3, TFPI | IDO1 3082/4885GAA 4023/4885ALDH1A1 3527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.